Clinical Trial Update: Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) [Phase 2, Phase 3]

View source ↗

Summary

The MEDALS trial evaluating memantine for disability in amyotrophic lateral sclerosis (ALS) across Phase 2 and Phase 3 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: University of Lisbon | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: COMPLETED